Founded in 1933, Vetoquinol S.A. operates as an independent, family-controlled veterinary pharmaceutical laboratory. The company's product portfolio is organized around four main therapeutic areas: antibiotics, anti-inflammatories, cardiology and nephrology treatments, and other products including anti-parasitics and nutritional supplements. Vetoquinol generates the majority of its revenue from the companion animal segment, which accounts for roughly 70% of sales, while livestock products make up the remainder. With a direct presence in 24 countries and sales in over 100, the company maintains a strong geographic footprint across Europe, the Americas, and the Asia-Pacific region. Its core strategy revolves around its "Essentials" range of high-margin products, which drives a significant portion of its global growth.
